MAY 16·Stock TitanLow
Lyra Therapeutics (LYRA) director surrenders 640 shares to issuer
Lyra Therapeutics director W. Bradford Smith reported a disposition of 640 common shares back to the company, leaving him with no directly held shares. This transaction, coded as a disposition to the issuer at $0.00 per share, was detailed in a Form 4 filing. The disposition implies the shares were returned to the company rather than being sold on the open market.